Johnson & Johnson Reports Q2 2021 Results

New Brunswick, N.J. (July 21, 2021) – Johnson &Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson &Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders.”OVERALL FINANCIAL RESULTS expand 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency3 Excludes the net impact of acquisitions and divestitures and translational currency4 Excludes intangible amortization expense and special itemsREGIONAL SALES RESULTS expand 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules2 Excludes the impact of translational currency3 Excludes the net impact of acquis...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news

Related Links:

More News: African Health | Amyloidosis | Arthritis | Bipolar | Canada Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cataract Removal | Cataracts | Conferences | COVID-19 | Dexamethasone | Ebola | Ebola Vaccine | Environmental Health | European Medicines Agency (EMA) | Government | Health Management | Heart | International Medicine & Public Health | Invega | Invega Sustenna | Legislation | Lung Cancer | Mania | Marketing | Medical Devices | Medical Ethics | Multiple Sclerosis | Myeloma | New Drug Applications | Non-Small Cell Lung Cancer | Oral Cancer | Orthopaedics | Outbreaks | Pandemics | Pediatrics | Pharmaceuticals | Podcasts | Profits and Losses | Prostate Cancer | Psoriasis | Psoriatic Arthritis | Remicade | Respiratory Medicine | Rheumatology | Schizophrenia | Science | Skin | Stelara | Strategic Planning | Vaccines | Websites | WHO | Zyrtec